Stage IIIB-IV lung adenocarcinoma
Conditions
Interventions
Case series:Nil
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Group 1: untreated stage IV NSCLC patients; Men or women aged 18 or older, 75 or older, with a life expectancy of 12 weeks or more;Pathological or cytologic diagnosis of stage IV lung cancer; Agree to collect the peripheral blood of patients at the specified time point; Willing to have no pregnancy plan in the next 6 months and voluntarily take effective contraceptive measures; The informed consent is signed before the test, and the content, process and possible adverse reactions of the test are fully understood, and the study can be completed according to the requirements of the test program. Enrolled population 2: Stage IV NSCLC patients with progression after first - and second-generation TKI treatment; Men or women aged 18 or older, 75 or older, with a life expectancy of 12 weeks or more;Pathological or cytological diagnosis of stage IV lung adenocarcinoma;Patients with first - and second-generation egfr-tki sensitive mutations and disease progression after first - and second-generation egfr-tki before treatment; Agree to collect the peripheral blood of patients at the specified time point; Willing to have no pregnancy plan in the next 6 months and voluntarily take effective contraceptive measures; The informed consent is signed before the test, and the content, process and possible adverse reactions of the test are fully understood, and the study can be completed according to the requirements of the test program.
Exclusion criteria
Exclusion criteria: Group 1: With a history of malignancy in the past 5 years; The patients had received chemotherapy or targeted therapy before enrollment. Patients with peripheral blood collection at specified time points are not accepted or unwilling to provide clinical information; Female subjects are in lactation period or positive serum pregnancy results during screening or testing; Patients have other systemic diseases that are difficult to control (such as severe heart disease). Group 2: Had a history of malignant tumor in the past 5 years;Patients with peripheral blood collection at specified time points are not accepted or unwilling to provide clinical information; Female subjects are in lactation period or positive serum pregnancy results during screening or testing; Patients have other systemic diseases that are difficult to control (such as severe heart disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor cell; | — |
Contacts
Public ContactPanwen Tian
West China Hospital, Sichuan University
Outcome results
None listed